Pregabalin controlled release - Pfizer
Alternative Names: GRO 12 - Pfizer; Lyrica CR; MR-1- Pfizer; MR-2- Pfizer; Pregabalin CR; Pregabalin ERLatest Information Update: 31 Dec 2021
At a glance
- Originator Pfizer
- Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Gabapentinoids; Neuroprotectants; Small molecules
- Mechanism of Action CACNA2D1 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Neuropathic pain; Postherpetic neuralgia
- Phase III Fibromyalgia
- Discontinued Epilepsy
Most Recent Events
- 24 Sep 2021 Discontinued - Phase-III for Epilepsy (Adjunctive treatment) in Czech Republic, Poland, Germany, Thailand, USA, Mexico, Serbia, Serbia, Bosnia-Herzegovina, India, Russia, Argentina, Singapore, Romania, Puerto Rico, Malaysia, Hungary, Bulgaria, Hong Kong, Hong Kong, Hong Kong (PO)
- 31 Oct 2017 Pfizer expects launch of Pregabalin controlled release for Neuropathic pain associated with diabetic peripheral neuropathy in USA in January 2018
- 12 Oct 2017 Registered for Neuropathic pain and Postherpetic neuralgia in USA (PO)